Bayer's Regulatory Run in Asia Sharpens the Contrast With Its Unresolved US Legal Front

Bayer gains regulatory wins in China and Japan for its pharma pipeline, while investors await the September Roundup settlement hearing.

The pharmaceutical division that Bayer has long promised as its growth engine is quietly accumulating evidence to back that claim. Within the span of a week, the Leverkusen-based group has notched regulatory milestones on two Asian fronts, adding tangible substance to a pipeline narrative that has often been overshadowed by the legal baggage of its Monsanto acquisition.

The most recent development came out of Beijing, where China's National Medical Products Administration accepted for review the marketing application for Aflibercept 8 mg, targeted at macular oedema following retinal vein occlusion. That filing rests on data from the phase III QUASAR programme. Days earlier, Japanese authorities granted approval to Hyrnuo for unresectable non-small cell lung cancer carrying HER2 mutations. Together, the two announcements underscore a portfolio that is advancing simultaneously in oncology and ophthalmology, even as the group's agricultural arm wrestles with structural headwinds and the glyphosate litigation overhang persists.

A September Date That Carries the Weight of $7.25 Billion

For all the pipeline progress, the calendar's most consequential entry remains the rescheduled US court hearing on the proposed Roundup settlement. Originally set for 19 August, the session to approve the $7.25 billion agreement was postponed at Bayer's own request and will now take place on 14 September. Until that date, the legal picture in the United States stays unresolved, and investors continue to price in that uncertainty as a persistent drag on sentiment.

The timing is awkward in one sense: the company enters that pivotal hearing with a string of positive regulatory headlines behind it, yet the financial exposure tied to the Monsanto legacy remains a multi-billion-dollar question mark that no pipeline win can fully neutralise.

Operating Metrics Point in the Right Direction

The mid-August quarterly update offered some reassurance on the fundamentals. Bayer reported currency-adjusted revenue growth of 2.2 percent to €10.9 billion, with EBITDA before special items coming in at €2.1 billion. Chief executive Bill Anderson framed the results as evidence that the group is on track to hit its full-year targets. Debt reduction has also moved up the agenda, a priority that carries particular weight given the scale of the legal liabilities still in play.

That combination of stabilised operations and a visibly maturing pharma pipeline has given the share price a firmer footing in recent months. The stock currently trades at €48.83, roughly 9.3 percent below its 52-week high of €53.86 touched in early July. More striking is the distance travelled from the November trough of €25.78 — a recovery of some 89 percent that speaks to how far sentiment has shifted since the darkest days.

Divergent Analyst Views Reflect the Core Tension

The Street remains split on Bayer, and the gap between two recent calls captures the dilemma neatly. The DZ Bank lifted its fair value to €60 in early August with a "Buy" rating, while Jefferies held firm at "Hold" with a €46 price target days later. That spread is essentially the debate about Bayer in miniature: operational momentum and regulatory wins on one side, unresolved litigation and leverage concerns on the other.

Munich Congress Adds Another Data Point

Before the September hearing, investors get one more piece of evidence to weigh. Bayer is slated to present fresh phase III data from its cardiovascular, renal and secondary prevention programmes at the ESC Congress in Munich, running from 28 to 31 August. The presentation will offer an early read on how robust the study landscape is in a therapeutic area the company considers strategically important. With the stock trading about 2.2 percent above its 50-day moving average of €47.75, the technical picture suggests the medium-term uptrend remains intact — but the next decisive move likely hinges on what happens in a US courtroom rather than in a Japanese or Chinese regulator's office.

Until mid-September, the market is left to weigh a steady drumbeat of pipeline news against a legal calendar that refuses to fade into the background. The regulatory wins in Asia provide genuine substance, but the glyphosate question will keep exerting its pull on the share price until the court delivers its answer.